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JWA, Moxon JWD, Dudfield M, Ingle L. Differential improve-
ments in lipid profiles and Framingham recurrent risk score in
patients with and without diabetes mellitus undergoing long-
term cardiac rehabilitation. Arch Phys Med Rehabil 2011;92:
1382-7.
Objective: To determine whether lipid profiles and recurrent
coronary heart disease (CHD) risk could be modified in pa-
tients with and without diabetes mellitus undergoing long-term
cardiac rehabilitation (CR).
Design: Retrospective analysis of patient case records.
Setting: Community-based phase 4 CR program.
Participants: Patients without diabetes (n154; 89% men;
ean  SD age, 59.68.5y; body mass index [BMI],
7.03.5kg/m2) and patients with diabetes (n20; 81% men;
ean age, 63.08.7y; BMI, 28.73.3kg/m2) who completed
15 months of CR.
Interventions: Exercise testing and training, risk profiling,
and risk-factor education.
Main Outcome Measures: Cardiometabolic risk factors and 2-
o 4-year Framingham recurrent CHD risk scores were
ssessed.
Results: At follow up, a significant main effect for time was
evident for decreased body mass and waist circumference and
improved low-density lipoprotein cholesterol (LDL-C) level
and submaximal cardiorespiratory fitness (all P.05), showing
the benefits of CR in both groups. However, a significant
group-by-time interaction effect was evident for high-density
lipoprotein cholesterol (HDL-C) level and total cholesterol
(TC)/HDL-C ratio (both P.05). TC/HDL-C ratio improved
5.01.5 to 4.41.3) in patients without diabetes, but showed
o improvement in patients with diabetes (4.81.6 v 4.91.6).
Conclusions: We showed that numerous anthropometric, sub-
aximal fitness, and cardiometabolic risk variables (especially
DL-C level) improved significantly after long-term CR. How-
ver, some aspects of cardiometabolic risk (measures incorpo-
ating TC and HDL-C) improved significantly in only the
ondiabetic group.
Key Words: Cardiac rehabilitation; Cardiometabolic risk;
ardiorespiratory fitness; Exercise training; High-density lipo-
rotein cholesterol; Low-density lipoprotein cholesterol; Reha-
ilitation; Type 2 diabetes.
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SEVERAL RECENT REPORTS from contemporary largeinternational databases, such as the REeduction of Athero-
thrombosis for Continued Health Registry, showed that stable
outpatients with coronary heart disease (CHD), especially
those with concomitant diabetes, experience high rates of sub-
sequent CHD events despite the use of various standard med-
ications and medical treatments.1 International survey data also
showed substantial residual cardiometabolic risk in patients
with CHD, especially obesity, dyslipidemia, increased blood
pressure, and impaired glucose tolerance. These are highly
prevalent, largely undertreated, and undercontrolled.2-4
The need for intensive, longitudinal, multimodal optimal
medical therapy in high-risk CHD groups5 has been reiterated
recently.6-10 Several studies11-16 reporting somewhat conflict-
ng results compared the effects of cardiac rehabilitation (CR)
etween patients with and without diabetes. Moreover, long-
erm lifestyle–induced improvements in cardiometabolic risk
actors in patients with type 2 diabetes without CHD also were
nconsistent.17,18 Therefore, the aim of our study was to eval-
ate the impact of a 15-month comprehensive outpatient CR
rogram on cardiometabolic and Framingham recurrent risk
rofiles in cardiac patients with and without diabetes mellitus.
List of Abbreviations
4S Scandinavian Simvastatin Survival Study
BMI body mass index
CHD coronary heart disease
CR cardiac rehabilitation
CRF cardiorespiratory fitness
DANSUK DANish StUdy of impaired glucose
metabolism in the settings of cardiac
rehabilitation
ECG electrocardiogram
ETT exercise tolerance test
EUROASPIRE European Action on Secondary
Prevention through Intervention to
Reduce Events
FRS Framingham risk score
HDL-C high-density lipoprotein cholesterol
LDL-C low-density lipoprotein cholesterol
RPE rating of perceived exertion
SCRIP Stanford Coronary Risk Intervention
Project
TC total cholesterol
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1383LIPID PROFILES IN DIABETICS AFTER REHABILITATION, CarrollMETHODS
articipants
Consecutive referrals were extracted from the Heart Watch
ommunity-based phase 4 CR program, Leeds, West York-
hire, United Kingdom. The program was developed and de-
ivered by Leeds City Council. All eligible patients had a
revious clinical diagnosis of CHD and were referred by their
eneral practitioner, consultant cardiologist, or hospital-based
R staff. Written informed consent for exercise testing and
raining was obtained from all patients. Ethical approval was
eceived from the Leeds Metropolitan University Faculty Eth-
cs Committee.
The CR program consisted of clinical evaluation, exercise
esting, risk-factor education, and counseling sessions on an
ngoing regular basis. All patients had been discharged from
he hospital for at least 12 weeks and were clinically stable,
symptomatic, and deemed capable to self-monitor and regu-
ate exercise training. Patients underwent a baseline clinical
valuation that included medical and cardiac history, anthro-
ometry, blood pressure, lipoprotein-lipid profiles, an electro-
ardiogram (ECG) at rest, and a submaximal cardiorespiratory
tness (CRF) test that included electrocardiography. Patients
ere reassessed at 3 and 15 months, including physician re-
iew of symptoms and medications and adherence to exercise
raining. Exercise adherence was confirmed by checking
eekly attendance registers of exercise classes.
CR medical staff were not responsible for ongoing therapeu-
ic management, but routinely informed patients’ general prac-
itioners of changes in symptoms, adverse cardiometabolic risk,
nd exercise testing abnormalities. We retrospectively ana-
yzed patient records to evaluate changes in these variables.
ur inclusion criteria were patients who (1) had undergone 2
onsecutive CRF tests and simultaneous blood tests at baseline
nd 15 months, (2) presented with a diagnosis of myocardial
nfarction or CHD or had undergone bypass surgery (coronary
rtery bypass grafting) or percutaneous transluminal coronary
ngioplasty, and (3) were nonsmokers. Patients with diabetes
ad a confirmed diagnosis of type 1 or 2 diabetes mellitus on
aseline referral. Patients with other diseases, such as valvular
eart disease, peripheral vascular disease, cardiomyopathies, or
ardiac arrhythmia syndromes, or those with a pacemaker were
xcluded. For purposes of our study, patients were stratified
nto 2 groups: (1) participants without and (2) with diabetes.
rocedures
Anthropometric data, including stature, body mass, and
aist circumference, were collected. Waist circumference was
easured at the level of the umbilicus, and hip circumference,
t the level of the greater trochanters (nearest 0.5cm) by using
flexible tape with the subject standing. Venous blood sam-
ling was conducted between 9.30 AM and 12.30 PM after an
vernight fast of at least 12 hours. Blood samples were drawn
ith minimal venous stasis from an antecubital vein into Mon-
vettea serum tubes. From January 1994 to August 1996, lipid
analyses were undertaken as routine clinical samples at
Seacroft Hospital Biochemistry Department, Leeds, accredited
by Clinical Pathology Accreditation (UK). Serum high-density
lipoprotein cholesterol (HDL-C) was measured in all normoli-
pemic samples (fasting triglycerides 4.0mmol/L) by using
the heparin manganese-chloride method. The laboratory sub-
scribed to the UK National External Quality Assurance Scheme
during the study period. Lipid analyses were performed on a
Hitachi 747 analyzerb using Boehringer Mannheimb reagents at
the Leeds General Infirmary. HDL-C level was determined by tusing the polyethylineglycol/aminophenazone method, with
coefficients of variation for low and high HDL-C levels of
6.3% to 13.3%. Maximum coefficients of variation for choles-
terol and triglyceride levels derived from external quality as-
surance schemes were approximately 5%. Total cholesterol
(TC)/HDL-C ratio was calculated as an index of lipid-associ-
ated CHD risk and is supported by both its superior predictive
power compared with TC, low-density lipoprotein cholesterol
(LDL-C), or HDL-C levels and lower within-person variabil-
ity.19
Systolic (Korotkoff phase I) and diastolic (Korotkoff phase
V) blood pressures at rest were determined manually by using
a mercury sphygmomanometer.c These measurements usually
ere obtained from the right arm with the subject in a sitting
osition. The lower of 2 consecutive measurements obtained
ithin 10 minutes was used. The Framingham Recurrent Risk
odel20 (Framingham risk score [FRS] model) was used to
etermine recurrent CHD risk for 2 and 4 years. The multivar-
ate model included age, sex, TC level, HDL-C level, current
moking status, and presence of diabetes. Systolic blood pres-
ure also was used in only women.
An ECG at rest was obtained with the subject in the standing
osition before the exercise tolerance test (ETT). The exercise
est was conducted on a Marquette Max treadmilld using a
2-minute stage incremental protocol.21 Patients were encour-
aged to exercise up to 85% of age-predicted maximum heart
rate (220age) or a “very hard” rating of perceived exertion
(RPE 17) using the Borg scale.22 However, the ETT was
terminated if a patient presented with symptoms highlighted as
contraindications by the American College of Sports Medi-
cine.23 Submaximal exercise testing was conducted in a non-
hospital setting that was medically supervised. Following local
cardiologist advice, the higher risk associated with maximal
exercise testing in cardiac patients was not considered appro-
priate for a community environment. Exercise test outcome
measures used in the present report were peak heart rate during
the final exercise stage completed, highest RPE, and exercise
test duration.
Exercise Training Program
The CR program was formally supervised by qualified ex-
ercise instructors. The exercise training program was 45 to 60
minutes (including warm-up stretching, aerobic/resistance-
based circuit training, and cool-down). Patients were strongly
encouraged to walk 30 minutes per day and attend exercise
classes on 3 nonconsecutive days per week. The circuit training
component involved six 4-minute stations, some with 8 differ-
ent exercises. Aerobic exercise included floor and treadmill
walking, leg cycling, arm-leg cycling, rowing ergometry, and
bench-stepping. Resistance and floor-based sets comprised 8
different exercises performed for up to 30 seconds each. All
patients wore a heart rate monitore during exercise. Exercise
ntensity was modified for each patient according to exercise
eart rate and electrocardiographic responses. Patients were
xpected to exercise to 40% to 85% of their submaximal heart
ate reserve (peak treadmill exercise heart rate minus heart rate
t rest), which was monitored by the exercise instructors.
tatistical Analysis
Continuous variables were presented as mean  SD, and
ategorical data, as percentage. An arbitrary level of 5% sta-
istical significance was used throughout (2 tailed). Indepen-
ent t tests and chi-square analysis were used to identify
ifferences in variables and proportions on cardioprotective
herapies between the nondiabetic and diabetic groups at base-
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1384 LIPID PROFILES IN DIABETICS AFTER REHABILITATION, Carrollline. Independent-samples t test was used to identify baseline
differences between groups. To identify potentially significant
group-by-time interactions, separate (group  time) analyses
of variance with repeated measures for time were used, and
when applicable, Bonferroni post hoc analysis was conducted.
Additional subgroup analyses were undertaken (1) excluding
all participants for whom lipid-lowering medication status
changed during the follow-up period and (2) for participants
not on statin therapy throughout the duration of the study.
SPSS software, Version 17.0f was used for statistical analyses,
nd significance was assumed at P.05.
RESULTS
Patients without diabetes (n154; 89% men; mean age,
9.68.5y; body mass index [BMI], 27.03.5kg/m2) and pa-
tients with diabetes (n20; 81% men; mean age, 63.08.7y;
BMI, 28.73.3kg/m2) completed 15 months of CR. All base-
line diagnostic, anthropometric, metabolic, and exercise vari-
ables are listed in table 1. Patients with diabetes tended to be
older and showed a more adverse anthropometric profile
(higher BMI and waist circumference). However, there were no
significant baseline differences between patients with and with-
out diabetes in any variables except for 2- and 4-year FRSs
(both P.001) and a significantly higher prevalence of statin
therapy at baseline in patients without diabetes (42% vs 29%).
Self-reported exercise training compliance rates at 15 months,
reported on clinical reassessment, were similar between groups
(diabetic group, 3.01.5 compared with nondiabetic group,
2.90.9 sessions/wk). Exercise test results showed that tread-
mill duration increased from 10.1 to 12.2 minutes in patients
without diabetes and 8.8 to 10.4 minutes in patients with
diabetes (both P.05). Peak RPE and submaximal heart rate
attained on the treadmill test did not differ between groups at
baseline and follow-up (see table 1).
A main effect for time was evident for anthropometric vari-
ables (decreased body mass and waist circumference), LDL-C
level (decreased), FRS at 4 years (decreased), TC level (de-
creased), and cardiorespiratory fitness (increased submaximal
Table 1: Anthropometric, Metabolic, and Exercise Tes
Without an
Variable
Baseline
Nondiabetic
15 mo
Nondiabetic
BMI (kg/m2) 27.03.5 26.83.5
Body mass (kg) 79.012.0 78.812.3
Waist circumference (cm) 95.29.6 94.49.5 1
Systolic BP at rest (mmHg) 143.320.0 141.320.8 1
Diastolic BP at rest (mmHg) 85.611.2 83.89.4
HR at rest (beats/min) 66.514.3 65.512.5
TC (mmol/L) 5.481.01 5.140.89
HDL-C (mmol/L) 1.170.30 1.240.34
Triglycerides (mmol/L) 1.821.26 1.600.86
LDL-C (mmol/L) 3.540.93 3.200.82
TC/HDL-C ratio 4.981.51 4.401.28
Exercise HR peak (beats/min) 126.619.0 128.918.5 1
Exercise RPE peak 14.71.9 15.21.7
Exercise duration (min) 10.12.7 12.22.7
FRS, 2 y (%) 8.52.4 7.92.2
FRS, 4 y (%) 17.13.4 15.14.1
OTE. Values expressed as mean  SD unless noted otherwise. Pa
bbreviations: ANOVA, analysis of variance; BP, blood pressure; HR, hea
Significant baseline differences between patients without and with diab
Arch Phys Med Rehabil Vol 92, September 2011exercise test duration; P.05 in all cases), showing the benefit
of exercise training in both groups at follow-up (see table 1). A
trend toward lower diastolic blood pressure at rest over time
also was evident (P.069).
A group-by-time interaction effect was evident for HDL-C
level and TC/HDL-C ratio (P.05). In patients without diabe-
tes, TC/HDL-C ratios improved from baseline (5.01.5) to 15
months (4.41.3). In contrast, TC/HDL-C ratio showed no
improvement in patients with diabetes (4.81.6 vs 4.91.6).
FRS at 4 years improved in the nondiabetic (17.1%3.4% vs
15.1%4.1%) and diabetic groups (22.2%4.1% vs
21.6%5.0%). A significant group effect (nondiabetic group
lower than diabetic group) was evident for FRS (P.05). We
adjusted our analyses to examine any influence of statin therapy.
A subgroup analysis was performed on all patients with no change
in statin therapy at 15 months (nondiabetic group, n128; diabetic
group, n16). This included patients for whom statin therapy was
unchanged and those not prescribed statins at any point. We found
that the interaction effect remained (all P.05) for HDL-C level,
TC/HDL-C ratio, and FRS at 4 years. The analysis was re-run for
all patients not on statin therapy at baseline and with no change
in statin therapy status at follow-up (nondiabetic group, n71;
diabetic group, n10) (table 2). A group-by-time interaction
effect was evident for HDL-C level in this subgroup of patients
(P.05). In patients with CHD, HDL-C levels improved from
baseline (1.180.34mmol/L) to 15 months (1.270.40mmol/
L). HDL-C levels decreased in the diabetic group (1.220.31
vs 1.090.25mmol/L). However, no significant time or inter-
action effect in TC/HDL-C ratio or FRS at 4 years (P for
interaction effect.125 and P.087, respectively) was ob-
served (data not shown). The proportion of participants using
diabetic medication was unchanged (see table 2).
DISCUSSION
We showed that anthropometric and submaximal fitness vari-
ables and LDL-C levels improved significantly in both the non-
diabetic and diabetic groups after long-term (15mo) CR incorpo-
rating structured aerobic/resistance exercise training. Most
riables: Baseline and 15-Month Follow-up in Patients
h Diabetes
Repeated-Measures ANOVA P
line
etic
15 mo
Diabetic Time Group
Time  Group
Interaction
3.3 28.32.9 .084 .058 .403
11.3 81.710.1 .033 .201 .125
8.9* 98.67.3 .001 .018 .054
25.0 145.217.8 .133 .224 .536
11.2 83.614.8 .069 .835 .622
16.8 73.315.7 .570 .014 .376
1.49 5.091.05 .007 .681 .734
0.25 1.090.22 .842 .211 .023
1.01 2.101.26 .312 .092 .377
1.23 3.180.92 .011 .629 .472
1.60 4.911.59 .074 .535 .024
24.3 129.122.3 .467 .773 .542
1.5 15.21.9 .282 .633 .509
3.2 10.43.5 .0001 .011 .323
2.7* 11.52.8 .123 .0001 .055
4.1* 21.65.0 .114 .0001 .051
without diabetes, n151; patients with diabetes, n20.t Va
d Wit
Base
Diab
28.7
83.4
01.5
50.0
86.7
72.9
5.36
1.15
2.11
3.37
4.84
28.9
15.1
8.8
11.5
22.2
tients
rt rate.
etes (P.05).
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1385LIPID PROFILES IN DIABETICS AFTER REHABILITATION, Carrollinpatient and outpatient CR programs or exercise training studies
typically ranged from only 6 weeks24 to 3 months.14,25,26 We
ound that HDL-C level improved in the nondiabetic group after
omprehensive CR. We report significant increases in the propor-
ion of patients prescribed statin therapy, which increased by
pproximately 10% in patients with and without diabetes. These
hanges in coronary risk factors were consistent with earlier
eports,11,26 including a randomized controlled trial17 showing
lipid improvements, except for HDL-C level in 1 study.11 An
earlier short-term study showed similar nonsignificant changes in
risk factors in a large cohort of patients with diabetes.13
Our findings are consistent with other multimodal intensive
interventions that significantly improved cardiometabolic risk
factors. Favorable intervention changes in cardiometabolic risk
compared with relatively small changes in the usual-care group
also were shown in the randomized Stanford Coronary Risk
Intervention Project (SCRIP) 4-year study.27 However, only a
mall proportion of patients with diabetes were randomly as-
igned (10%–13%) in SCRIP. Lifestyle changes were more
ffective than metformin for decreasing the incidence of dia-
etes in high-risk patients with impaired glucose metabo-
ism.28,29 In secondary prevention settings, a 12-month Danish
tudy investigated stepwise intensive CR (DANish StUdy of
mpaired glucose metabolism in the settings of cardiac reha-
ilitation [DANSUK]),30 including an initial 6-week period of
upervised exercise training, on risk-factor profile in 104 pa-
ients with type 2 diabetes or impaired glucose tolerance.
articipants were randomly assigned to hospital-based rehabil-
tation compared with usual care. In patients with diabetes,
aist circumference, TC level, and LDL-C level (3% and
.6%, respectively), but not triglyceride and HDL-C levels,
ecreased significantly compared with the usual-care group. Of
ote, proportions of patients in the DANSUK usual-care and
ntervention groups receiving statin therapy at study end were
igh (82% and 94%, respectively).
Consistent with other reports, our patients with diabetes had
ignificantly lower exercise capacity than patients without di-
betes at baseline13,14,24 and had similar relative improvements
ith exercise training. An increase of 1mL·kg1·min1 in peak
oxygen uptake is equivalent to a 9% decrease in cardiovascu-
lar-related mortality in secondary prevention settings.31 Al-
Table 2: Proportions of Patients Using Diabetic and
Cardioprotective Medications and Attainment of Therapeutic
Control of TC, BP, and Clinical Obesity in Accordance With
Professional Society Guidelines (Joint European
Society/EUROASPIRE Surveys): Baseline and 15-Month Follow-up
in the CAR and CDM Groups
Variable
Baseline 15 mo
Nondiabetic Diabetic Nondiabetic Diabetic
Diabetic medication (%) NA 39 NA 46
Statins (%) 40 35 51 45
-Blockers (%) 42 46 41 46
ACE inhibitors (%) 19 23 27 23
Diuretics (%) 16 31 16 31
TC (4.5mmol/L) 18 35 23 25
Systolic BP (140mmHg) 38 40 43 35
Diastolic BP (90mmHg) 56 45 70 70
BP (130/80mmHg) 12 10 12 25
BMI (30.0kg/m2) 80 75 80 70
NOTE. Values expressed as %.
Abbreviations: ACE, angiotensin-converting enzyme; BP, blood
pressure; NA, not applicable.though we did not measure maximal oxygen uptake, we found aan improvement in mean submaximal oxygen uptake of 3 to
4mL·kg1·min1, or approximately 1 metabolic equivalent.23
Recently, Mourot et al24 reported similar short-term improve-
ments in exercise capacity after a multidisciplinary CR pro-
gram in a large cohort of patients with CHD with and without
type 2 diabetes. This generally was consistent with other stud-
ies that reported improvements of 38% in patients with diabetes
and 34% in patients without diabetes after 3 months of exercise
training24 or 26% in patients with diabetes after 10 weeks of
training.13 Verges et al12 reported less impressive improve-
ents in peak oxygen uptake after 2 months of aerobic training
13% in patients with diabetes). Likewise, exercise capacity did
ot significantly improve in patients with type 2 diabetes in the
R group compared with usual care in DANSUK.30 It is not
clear why these discrepancies exist; however, it likely is caused
by a number of factors, including differences in participant
baseline characteristics (age, medication use, disease severity,
prevalence of comorbid conditions, volume/intensity of exer-
cise training), training adherence, and CRF measurement meth-
ods.
Based on the FRS, we showed that risk for a recurrent
cardiac event within 4 years decreased after 15 months in the
nondiabetic group compared with patients with diabetes. The
higher risk reported in the diabetic group was consistent with
previous findings. A revised Framingham CHD risk score32
also decreased significantly in the intensive intervention group
in SCRIP compared with usual care. However, in the present
investigation, only approximately 20% of study participants
attained the Joint European Societies treatment target for TC
level (4.5mmol/L). In comparison, the proportion with in-
creased cholesterol levels decreased from 94.5% in European
Action on Secondary Prevention through Intervention to Re-
duce Events (EUROASPIRE) 1 (1995–1996) to 42.6% in
EUROASPIRE III (2006–2007), largely because of the in-
creased use of statins. Likewise, the mentioned intensive CR
studies reported end-study statin therapy rates consistently in
the region of 90% in CR patients or active intervention
groups.26,27
Clinicians should consider more aggressive lipid lowering
(statin monotherapy or combination regimens)33,34 and angio-
ensin-converting enzyme–inhibitor therapy in patients with
HD, especially those with diabetes, to improve cardiometa-
olic risk and estimated cardiovascular endpoints. However,
everal studies showed cardiometabolic risk profile to deterio-
ate significantly after short-term CR on long-term follow-
p.35,36
Study Limitations
Several important study limitations should be highlighted.
First, this was a retrospective analysis of patient case records.
Patients were recruited over a considerable time frame, many
before the publication and widespread dissemination of the
benefits of several cardioprotective therapies in secondary pre-
vention settings and professional society guidelines. Only 13%
of our sample (all without diabetes) was recruited before pub-
lication of the Scandinavian Simvastatin Survival Study (4S).37
Most participants (84%), including most patients with diabetes,
were recruited between the seminal publication dates of the 4S
and subsequent Heart Protection Study38 in 2002. Only 5
articipants were recruited post-2002. Participants were not
andomly, assigned and both selection and referral bias may be
resent. We were not able to provide a comparison control
roup of cardiac patients not undergoing exercise training
ntervention. Accordingly, the influence of regression to the
ean for cardiometabolic and cardiorespiratory fitness vari-bles should be considered. Most patients referred for rehabil-
Arch Phys Med Rehabil Vol 92, September 2011
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1386 LIPID PROFILES IN DIABETICS AFTER REHABILITATION, Carrollitation were men, and the findings may not be generalizable to
female outpatients without diabetes. In this cohort, referred
patients with diabetes constituted only a small proportion of
patients and relatively few completed 15 months of CR. The
first EUROASPIRE survey (1995–1996)39 also reported low
representation of both women and patients with diabetes
(20.7% and 17.4%, respectively). It also is important to con-
sider that the FRS is not without limitations. The risk algorithm
was derived from the original Framingham cohort, predating
many medical and surgical treatment advances for secondary
prevention of CHD. Obesity and associated conditions such as
diabetes were far less prevalent in the cohort of patients with
preexisting cardiac disease in the original Framingham study.20
Other important risk factors in secondary prevention, such as
ischemic history, other vascular comorbid conditions,2 cardio-
rotective medications, and contemporary risk biomarkers
such as N-terminal pro-brain natriuretic peptide or high-sen-
itivity C-reactive protein) were not considered. Finally, al-
hough our study showed improvements in Framingham recur-
ent risk estimation, it was not designed to assess subsequent
ardiovascular events. Further studies of larger cohorts with
onger follow-up are required to show subsequent clinical
rognosis in patients with and without diabetes.
CONCLUSIONS
We showed that numerous anthropometric, submaximal fit-
ess, and cardiometabolic risk variables (especially LDL-C
evel) improved significantly after long-term CR. However,
ome aspects of cardiometabolic risk (measures incorporating
C and HDL-C levels) improved significantly in only the
ondiabetic group. Optimal medical therapy, a healthy lifestyle
ith regular physical exercise, and coronary interventions are
nterdependent treatment strategies.40 This long-term outpa-
tient community-based CR program appeared efficacious in
decreasing residual risk in CHD groups.
Acknowledgments: We thank Mr Steve Lawton for continued
coordination of the Heart Watch program.
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